Boothbay Fund Management’s XBiotech XBIT Stock Holding History

Boothbay Fund Management’s Portfolio XBIT Stock Details XBIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-21,079	Closed	-$107K	–	899
2018 Q4	$107K	Buy	+21,079	New	+$86.5K	0.02%	553

Other funds holding XBIT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

TEE

Tibra Equities Europe London, United Kingdom $90.4M AUM 37.81% 1-Year Est. Return

Boothbay Fund Management's XBIT Position: Q1 2019 in Review

Boothbay Fund Management sold out of XBiotech (XBIT) in Q1 2019, closing a stake of 21,079 shares — an estimated $107K sold.

Boothbay Fund Management first reported a position in XBIT in Q4 2018 and held it in 1 quarter. The position peaked at $107K in Q4 2018. 38 funds tracked by Wall St. Rank hold XBIT as of Q1 2019.

Boothbay Fund Management reported no remaining XBiotech position as of Q1 2019 after selling out during the quarter.
Boothbay Fund Management sold 21,079 XBiotech shares in Q1 2019, an estimated $107K.
Boothbay Fund Management first reported a position in XBiotech in Q4 2018 and held it in 1 quarter.
Boothbay Fund Management's XBiotech position peaked at $107K in Q4 2018.
38 funds tracked by Wall St. Rank held XBiotech as of Q1 2019.

Based on Boothbay Fund Management's 13F filing for Q1 2019, filed 15 May 2019.